Fig. 1From: A prospective cohort study on the pharmacokinetics of nivolumab in metastatic non-small cell lung cancer, melanoma, and renal cell cancer patientsPatient examples. Example of two subjects (2010: NSCLC, 1015: melanoma patient) showing concentrations of nivolumab (mg/L) versus time (weeks), with received administrations of nivolumab being marked as open triangles. Single measurements are represented by closed circles. a Note that patient 2010 experienced several dose delays followed by a decrease of nivolumab concentrations that was in line with the approximate half-life time of 25 days, whereas b patient 2015 has had no dose delays and demonstrated a time to steady state concentrations of approximately 20 weeksBack to article page